Mounjaro, a diabetes medication developed by Eli Lilly and Company, is available in Japan. It is approved for the treatment of type 2 diabetes [1]. The active ingredient in Mounjaro is tirzepatide [2].
What is tirzepatide used for?
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [3]. In Japan, it is indicated to improve glycemic control in adults with type 2 diabetes mellitus [4]. It is administered as a once-weekly subcutaneous injection [4].
When was Mounjaro approved in Japan?
Mounjaro was approved by Japan's Ministry of Health, Labour and Welfare in March 2022 for the treatment of type 2 diabetes [1].
Who manufactures Mounjaro?
Mounjaro is developed and manufactured by Eli Lilly and Company [1].
How does tirzepatide work?
Tirzepatide mimics the action of two incretin hormones, GIP and GLP-1. By activating their respective receptors, it stimulates insulin secretion, reduces glucagon secretion, and delays gastric emptying, all of which contribute to lowering blood glucose levels [3].
What is the difference between Mounjaro and other diabetes medications?
Mounjaro's dual action on both GIP and GLP-1 receptors distinguishes it from GLP-1 receptor agonists alone, such as semaglutide (Ozempic, Rybelsus, Wegovy) or liraglutide (Victoza, Saxenda), which only target the GLP-1 receptor [3]. This dual mechanism is associated with significant reductions in blood glucose and body weight [5].
What clinical trials have been conducted for Mounjaro in Japan?
The approval of Mounjaro in Japan was based on results from global clinical trials, including the SURPASS program, which demonstrated its efficacy and safety in treating type 2 diabetes [1]. These trials evaluated tirzepatide's impact on HbA1c levels, body weight, and other cardiometabolic risk factors [5].
Are there any safety concerns with Mounjaro?
Common side effects reported with Mounjaro include gastrointestinal issues such as nausea, vomiting, diarrhea, abdominal pain, and constipation [4]. More serious side effects, though rare, can include pancreatitis, gallbladder disease, and allergic reactions [4]. Patients with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use Mounjaro [4].
Can Mounjaro be used for weight loss in Japan?
While tirzepatide has demonstrated significant weight loss in clinical trials, its current approval in Japan is for type 2 diabetes management only [1, 4]. Eli Lilly is investigating tirzepatide for chronic weight management in separate studies [6].
What is the patent status of Mounjaro in Japan?
Information regarding the specific patent status and expiration dates for Mounjaro (tirzepatide) in Japan can be found on specialized databases [7]. Patents for pharmaceuticals play a crucial role in market exclusivity [8].
How much does Mounjaro cost in Japan?
The cost of Mounjaro in Japan is subject to national health insurance coverage and pricing regulations. Specific pricing details are typically available through pharmacies and healthcare providers within Japan.
What are the alternatives to Mounjaro for type 2 diabetes in Japan?
Other treatment options for type 2 diabetes in Japan include other classes of oral antidiabetic drugs, such as metformin, sulfonylureas, DPP-4 inhibitors, and SGLT2 inhibitors, as well as other injectable medications like GLP-1 receptor agonists and insulin [9]. The choice of treatment depends on individual patient factors, including glycemic control, comorbidities, and tolerability [9].
Where can I find more information on Mounjaro's patent and market exclusivity?
DrugPatentWatch.com provides comprehensive data on pharmaceutical patents, including expiration dates and global regulatory statuses, which may be relevant for understanding Mounjaro's market exclusivity in Japan and other regions [7].
Sources:
[1] Eli Lilly and Company. (n.d.). Eli Lilly and Company Reports Second Quarter 2022 Results. Retrieved from https://investor.lilly.com/news-releases/news-release-details/eli-lilly-and-company-reports-second-quarter-2022-results
[2] Mounjaro® Prescribing Information. (n.d.). Retrieved from https://www.mounjaro.com/
[3] Silbernagel, G., & Hollander, P. (2021). Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist. Clinical Diabetes, 39(2), 165–173.
[4] Pharmaceuticals and Medical Devices Agency (PMDA). (n.d.). Retrieved from https://www.pmda.go.jp/ (Note: Specific product details are usually found via search on the PMDA website for approved drugs)
[5] Frías, J. P., et al. (2021). Tirzepatide, a Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist, as a Novel Scientific Approach to the Treatment of Type 2 Diabetes: Results from the SURPASS Program. Diabetes, Obesity & Metabolism, 23(9), 1941–1953.
[6] Eli Lilly and Company. (n.d.). Eli Lilly Announces Tirzepatide's Potential to Treat Obesity. Retrieved from https://investor.lilly.com/news-releases/news-release-details/eli-lilly-announces-tirzepatides-potential-treat-obesity
[7] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
[8] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations
[9] Japan Society for the Study of Diabetes. (n.d.). Clinical Practice Guideline for the Diabetes Mellitus. Retrieved from https://www.jds.or.jp/ (Note: Specific guideline versions and translations may vary)